Home Cart Sign in  
Chemical Structure| 152-95-4 Chemical Structure| 152-95-4

Structure of Sophoricoside
CAS No.: 152-95-4

Chemical Structure| 152-95-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Sophoricoside is an isoflavone glycoside present in fruits of sophora japonica L. with anti-inflammatory and immunosuppressive effects.

Synonyms: Genistein 4′-O-glucoside

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Sophoricoside

CAS No. :152-95-4
Formula : C21H20O10
M.W : 432.38
SMILES Code : OC1=C(C(C(C2=CC=C(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)C=C2)=CO4)=O)C4=CC(O)=C1
Synonyms :
Genistein 4′-O-glucoside
MDL No. :MFCD01075138
InChI Key :ISQRJFLLIDGZEP-CMWLGVBASA-N
Pubchem ID :5321398

Safety of Sophoricoside

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Human mast cell line HMC-1 1–50 µM 1–12 hours Sophoricoside significantly inhibited PMACI-induced histamine release and the production of inflammatory cytokines (TNF-α, IL-8, and IL-6), and suppressed the activation of NF-κB and caspase-1. Molecules. 2013 May 22;18(5):6113-27
C2C12 myotubes 1–10 µM 12 hours Increased glucose uptake by C2C12 myotubes in a dose-dependent manner. Molecules. 2013 Dec 13;18(12):15624-35
AML12 cells 50 and 100 µM 24 hours To evaluate the antioxidant effects of SOP on LPS-stimulated AML12 cells, results showed that SOP significantly reversed the LPS-induced increase in MDA levels and upregulated T-AOC and GSH-Px levels in a concentration-dependent manner Int J Mol Med. 2023 Sep;52(3):78
HepG2 cells 1–10 µM 24 hours Inhibited lipid accumulation in HepG2 cells in a dose-dependent manner. Molecules. 2013 Dec 13;18(12):15624-35
Neonatal rat cardiomyocytes (NRCMs) 10 or 50 µM 48 hours To evaluate the protective effect of Sop against PE-induced cardiomyocyte hypertrophy. Results showed that Sop significantly alleviated PE-induced NRCMs hypertrophy and reduced the mRNA and protein levels of hypertrophic marker genes (ANP, MYH7). Biosci Rep. 2020 Nov 27;40(11):BSR20200661

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
ICR mice and BALB/c mice Compound 48/80 or histamine-induced scratching behavior model and DNCB-induced atopic dermatitis model Oral 2 mg/kg Single administration (scratching behavior model) or continuous administration for 2 weeks (atopic dermatitis model) Sophoricoside significantly reduced compound 48/80 or histamine-induced scratching behaviors and improved DNCB-induced atopic dermatitis, while reducing serum IgE levels. Molecules. 2013 May 22;18(5):6113-27
C57BL/6 male mice Improved chronic CYP2D6-AIH mouse model and ConA-induced acute immune-mediated liver injury model Intraperitoneal injection 30 mg/kg Once daily for approximately 2 weeks To evaluate the therapeutic effects of SOP on autoimmune hepatitis, results showed that SOP significantly reduced serum ALT/AST levels, alleviated liver inflammation and fibrosis, and inhibited oxidative stress and NF-κB signaling pathway activation Int J Mol Med. 2023 Sep;52(3):78
C57BL6/J mice Starch-loaded model Oral 50, 100, 200 mg/kg Single dose Significantly lowered postprandial hyperglycemia in starch-loaded mice. Molecules. 2013 Dec 13;18(12):15624-35
Mice Transverse aortic constriction (TAC) surgery-induced cardiac hypertrophy model Gavage 80 or 160 mg/kg/day Once daily for 4 weeks To evaluate the protective effect of Sop against TAC-induced cardiac hypertrophy and dysfunction. Results showed that Sop significantly alleviated TAC-induced cardiac hypertrophy, myocardial fibrosis, and cardiac dysfunction, and activated the AMPK/mTORC1-mediated autophagy pathway. Biosci Rep. 2020 Nov 27;40(11):BSR20200661

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.31mL

0.46mL

0.23mL

11.56mL

2.31mL

1.16mL

23.13mL

4.63mL

2.31mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories